Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease

Lou, Da-jun; Zhu, Qing; Si, Xu-wei; Guan, Lili; Qin, You; Yu, Zhongming; Zhang, Aizhen; Li, Duo

doi:10.1016/j.jdiacomp.2014.04.008

Cited by 20 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are consistent with those of other similar investigations of the clinical effect of EPL and omega-3 PUFA (Li et al, 2000;Ohbayashi, 2004;Poongothai et al, 2005;Sas et al, 2013;Lou et al, 2014;Gundermann et al, 2016;Stepanov, 2016;Martinez-Rodriguez et al, 2017). The Kokran review (Lombardi et al, 2017), which includes 77 clinical trials with 6,287 NFLD patients examined, showed ambiguous data regarding efficacy of different pharmacological treatments including EPL, omega-3 PUFA and ALA use.…”

Section: Discussionsupporting

confidence: 93%

Biochemical screen correction possibilities in patients with non-alcoholic fatty liver disease with diabetes mellitus

Фейса

Ростока-Резнікова

Tovt-Korshynska

et al. 2018

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

The rationale for this study is the controversial data regarding the efficacy of hepatoprotectors and antioxidants for lipid profile correction in non-alcoholic fatty liver disease, the prevalence of which is increasing especially in association with diabetes mellitus. We examined 100 non-alcoholic fatty liver disease patients (40–75 years old) with concomitant type 2 diabetes mellitus (n = 73) or without it (n = 27), the groups were standardized by age and gender. In patients with non-alcoholic fatty liver disease with diabetes mellitus we revealed significantly higher rates of total cholesterol, triglycerides and atherogenic factor in association with a significantly lower high-density lipoproteins level versus the group of patients without concomitant diabetes. We recommended the modification of lifestyle as basic management of their condition to all patients, hypoglycemic therapy with metformin to persons with concomitant diabetes mellitus and rosuvastatin to patients with non-alcoholic fatty liver disease without diabetes. In addition, 25 patients received essential phospholipids (2 caps. 3 times a day) and omega-3 polyunsaturated fatty acids (1000 mg per day) for 3 months; 26 patients – α-lipoic acid (600 mg daily) for 3 months, 22 patients received rosuvastatin (10 mg daily), 27 patients with non-alcoholic fatty liver disease without diabetes mellitus received rosuvastatin (10 mg daily). We evaluated the treatment efficiency after 3 months treatment, and the remote consequences – 12 months after the start of combined treatment. After 3 months, the alanine-aminotransferase rate had decreased by 15.1% in the group taking combined essential phospholipids and ω3-polyunsaturated fatty acids and by 12.9% in the group taking alpha-lipoic acid, which was significantly larger than in the rosuvastatin group (7.5%); gamma-glutamate transpeptidase level decreased by 16.7%, 18.7% and 9.4% respectively indicating anticholestatic and hepatoprotective effect of both proposed treatment combinations. The same tendency of cytolysis and cholestasis processes inhibition was observed after 12 months as well. In conclusion, the combination of standard treatment with antioxidant and hepatoprotective agents (omega-3 polyunsaturated fatty acids with essential phospholipids or only alpha-lipoic acid) promotes both cytolysis and cholestasis syndromes inhibition in non-alcoholic fatty liver disease patients with concomitant type 2 diabetes mellitus.

show abstract

Section: Discussionsupporting

confidence: 93%

Biochemical screen correction possibilities in patients with non-alcoholic fatty liver disease with diabetes mellitus

Фейса

Ростока-Резнікова

Tovt-Korshynska

et al. 2018

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

show abstract

“…As such, the relative abundance of ω6 to ω3 PUFA in cells impacts the cellular inflammatory status (Calder, 2015; Simopoulos, 2002; Spadaro, 2008). Studies in humans (Lou, 2014) and mice (Depner, 2013a; Lytle, 2017) indicate that a high blood and hepatic ω6/ω3 PUFA ratio is associated with inflammation and NAFLD progression.…”

Section: Progression Of Benign Steatosis To Nashmentioning

confidence: 99%

Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease

Jump

Lytle

Depner

et al. 2018

Pharmacology & Therapeutics

112

101

View full text Add to dashboard Cite

Obese and type 2 diabetic (T2DM) patients have a high prevalence of nonalcoholic fatty liver disease (NAFLD). NAFLD is a continuum of chronic liver diseases ranging from benign hepatosteatosis to nonalcoholic steatohepatitis (NASH), cirrhosis and primary hepatocellular cancer (HCC). Because of its strong association with the obesity epidemic, NAFLD is rapidly becoming a major public health concern worldwide. Surprisingly, there are no FDA approved NAFLD therapies; and current therapies focus on the co-morbidities associated with NAFLD, namely, obesity, hyperglycemia, dyslipidemia, and hypertension. The goal of this review is to provide background on the disease process, discuss human studies and preclinical models that have examined treatment options. We also provide an in-depth rationale for the use of dietary ω3 polyunsaturated fatty acid (ω3 PUFA) supplements as a treatment option for NAFLD. This focus is based on recent studies indicating that NASH patients and preclinical mouse models of NASH have low levels of hepatic C ω3 PUFA. This decline in hepatic PUFA may account for the major phenotypic features associated with NASH, including steatosis, inflammation and fibrosis. Finally, our discussion will address the strengths and limitations of ω3 PUFA supplements use in NAFLD therapy.

show abstract

“…Omega-3 fatty acids are essential polyunsaturated fatty acids, a group that includes eicosapentaenoic and docosahexaenoic acids (DHA). In patients with DM2, plasma levels of omega-3 acids correlate negatively with insulin resistance and dyslipidemia [ 80 ]. Experimentally, an increased production of omega-3 in a diabetic mice model confers resistance to diet induced obesity and diabetes [ 81 ].…”

Section: Treatment Of Dyslipidemia: Its Impact On Dpnmentioning

confidence: 99%

Lipids: A Suitable Therapeutic Target in Diabetic Neuropathy?

Pérez-Matos

Morales-Álvarez

Mendivil

2017

Journal of Diabetes Research

View full text Add to dashboard Cite

Diabetic polyneuropathy (DPN) encompasses multiple syndromes with a common pathogenesis. Glycemic control shows a limited correlation with DPN, arguing in favor of major involvement of other factors, one of which is alterations of lipid and lipoprotein metabolism. Consistent associations have been found between plasma triglycerides/remnant lipoproteins and the risk of DPN. Studies in cultured nerve tissue or in murine models of diabetes have unveiled mechanisms linking lipid metabolism to DPN. Deficient insulin action increases fatty acids flux to nerve cells, inducing mitochondrial dysfunction, anomalous protein kinase C signaling, and perturbations in the physicochemical properties of the plasma membrane. Oxidized low-density lipoproteins bind to cellular receptors and promote generation of reactive oxygen species, worsening mitochondrial function and altering the electrical properties of neurons. Supplementation with specific fatty acids has led to prevention or reversal of different modalities of DPN in animal models. Post hoc and secondary analyses of clinical trials have found benefits of cholesterol reducing (statins and ezetimibe), triglyceride-reducing (fibrates), or lipid antioxidant (thioctic acid) therapies over the progression and severity of DPN. However, these findings are mostly hypothesis-generating. Randomized trials are warranted in which the impact of intensive plasma lipids normalization on DPN outcomes is specifically evaluated.

show abstract

Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease

Cited by 20 publications

References 21 publications

Biochemical screen correction possibilities in patients with non-alcoholic fatty liver disease with diabetes mellitus

Biochemical screen correction possibilities in patients with non-alcoholic fatty liver disease with diabetes mellitus

Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease

Lipids: A Suitable Therapeutic Target in Diabetic Neuropathy?

Contact Info

Product

Resources

About